News in brief

LabCorp in talks to buy PPD for $8Bn

LabCorp in talks to buy the CRO PPD for $8Bn

Unconfirmed reports suggest Laboratory Corporation of America Holdings (LabCorp) is in talks to acquire contract research organization Pharmaceutical Product Development LLC (PPD).

According to a Reuters report, a second party is taking part in the auction of PPD with LabCorp, but has not yet been identified

If LabCorp was to acquire PPD, the transaction's value would exceed the $5.7bn for which it purchased Covance in 2015.

PPD offers contract research services from inhalation products to biologics, for a wide range of indications, with headquarters in Wilmington, North Carolina. 

The firm has more than 18,500 employees worldwide and is owned by Carlyle Group LP and Hellman & Friedman LLC, which made the company private in 2011 for $3.9bn.

LabCorp is a North Carolina, US-based clinical lab network with a $14.3bn (€13.3bn) market cap. Last month, it acquired Mount Sinai’s clinical outreach laboratories, adding seven patient service centers to its network.

Related News

LabCorp has expanded its LaunchPad initiative to include Covance Drug Development. (Image: iStock/Pinkypills)

Covance plans closures – and expansions – as it aims to 'right-size'

LabCorp's Dave King

LabCorp outlines near-term goals following Covance integration

(Image: iStock/Weedezign)

LabCorp to acquire Mount Sinai assets

Evidera’s real world research services will further strengthen PPD’s peri- and post-approval capabilities. (Image: iStock/Nastco)

PPD completes Evidera acquisition, committed to seamless integration

Icon, PPD expand in Ireland

Icon, PPD expand further into Ireland with more jobs, warehousing space

Quintiles, Parexel, PPD lead all CROs in US trial totals, review finds

Quintiles, Parexel, PPD lead all CROs in US trial totals, review finds

Addition of PPD will not affect ongoing business with Parexel and Icon, says Pfizer

Pfizer reveals PPD as third strategic CRO partner

Related Products

See more related products